Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

February 9, 2016

Primary Completion Date

October 6, 2020

Study Completion Date

October 6, 2020

Conditions
Cutaneous T-cell Lymphoma (CTCL)Mycosis Fungoides (MF)Chronic Lymphocytic Leukemia (CLL)Diffuse Large B-Cell Lymphoma (DLBCL), ABC SubtypeAdult T-Cell Leukemia/Lymphoma (ATLL)
Interventions
DRUG

Cobomarsen

Trial Locations (19)

10065

Memorial Sloan Kettering Cancer Center, New York

Weill Cornell Medicine, New York

10467

Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx

19107

Thomas Jefferson University Hospital, Philadelphia

22003

Inova Melanoma and Skin Cancer Center / Inova Schar Cancer Institute, Fairfax

33136

University of Miami Sylvester Comprehensive Cancer Center, Miami

43210

The Ohio State University Comprehensive Cancer Center, Columbus

60611

Northwestern University; Department of Dermatology, Chicago

68198

University of Nebraska Medical Center, Omaha

77030

The University of Texas MD Anderson Cancer Center, Houston

80045

University of Colorado, Anschutz Medical Campus, Aurora

84112

Huntsman Cancer Institute, Salt Lake City

90095

UCLA Department of Medicine, Los Angeles

91010

City of Hope, Duarte

92093

UCSD Moores Cancer Center, La Jolla

92868

Chao Family Comprehensive Cancer Center at University of California, Irvine, Orange

94063

Stanford University Hospital and Clinics, Stanford

06510

Smilow Cancer Hospital at Yale-New Haven, New Haven

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
lead

miRagen Therapeutics, Inc.

INDUSTRY

NCT02580552 - Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL | Biotech Hunter | Biotech Hunter